Search Results - frank+lowery

5 Results

Sort By:

HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K

Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01. Description of Technology: Phosphatidylinositol-4,5-biphosphate...

Published: 4/16/2026 | Updated: 11/6/2024 | Inventor(s): Steven Rosenberg, NIkolaos Zacharakis, S M Rafiqul Islam, Samantha Seitter, Maria Parkhurst, Frank Lowery

Keywords(s):

Category(s): TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing

T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy

Summary: The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations. Description of Technology: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery

Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)

Summary: NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs. Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients

Summary: NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL). Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy

Summary: The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies. Description of Technology: Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Steven Rosenberg, Gregoire Altan-Bonnet, Sri Krishna, Paul Robbins, Frank Lowery

Keywords(s): act, Adoptive T Cell Therapy, Cancer Immunotherapies, CAR, CD-39 Receptor, CD3-Receptor, CD-69 Receptor, chimeric antigen receptor, Lowery, Rosenberg, T Cell Receptor, TCR, TILS, Tumor-Infiltrating T-Lymphocytes

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics